Childhood spinal muscular atrophy.

Anterior horn cell Disease-modifying therapy Motor neuron disease SMN1 gene Spinal muscular atrophy

Journal

Handbook of clinical neurology
ISSN: 0072-9752
Titre abrégé: Handb Clin Neurol
Pays: Netherlands
ID NLM: 0166161

Informations de publication

Date de publication:
2023
Historique:
medline: 28 8 2023
pubmed: 25 8 2023
entrez: 24 8 2023
Statut: ppublish

Résumé

Spinal muscular atrophy (SMA) is caused by biallelic mutations in the SMN1 (survival motor neuron 1) gene on chromosome 5q13.2, which leads to a progressive degeneration of alpha motor neurons in the spinal cord and in motor nerve nuclei in the caudal brainstem. It is characterized by progressive proximally accentuated muscle weakness with loss of already acquired motor skills, areflexia and, depending on the phenotype, varying degrees of weakness of the respiratory and bulbar muscles. Over the past decade, disease-modifying therapies have become available based on splicing modulation of the SMN2 with SMN1 gene replacement, which if initiated significantly modifies the natural course of the disease. Newborn screening for SMA has been implemented in an increasing number of centers; however, available evidence for these new treatments is often limited to a small spectrum of patients concerning age and disease stage.

Identifiants

pubmed: 37620083
pii: B978-0-323-98817-9.00030-2
doi: 10.1016/B978-0-323-98817-9.00030-2
pii:
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-58

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

David S Younger (DS)

Department of Clinical Medicine and Neuroscience, CUNY School of Medicine, New York, NY, United States; Department of Medicine, Section of Internal Medicine and Neurology, White Plains Hospital, White Plains, NY, United States. Electronic address: youngd01@nyu.edu.

Jerry R Mendell (JR)

Department of Neurology and Pediatrics, Center for Gene Therapy, Abigail Wexner Research Institute, The Ohio State University, Nationwide Children's Hospital, Columbus, OH, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH